Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Delayed Reaction: BioMarin Rises On Pegvaliase Data

This article was originally published in Scrip

Executive Summary

BioMarin Pharmaceutical Inc. has bounced back from a stock price slump that occurred after it reported that pegvaliase, the company's second therapy to treat phenylketonuria (PKU), met the primary endpoint in a Phase III clinical trial, but failed to meet a key secondary endpoint.

Advertisement

Related Content

Keeping Track: US FDA Approves Sickle Cell Therapy Endari; Array Submits Binimetinib Again
BioMarin Expects 30% Markdown For Orphan Pediatric Drug Brineura
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?

Topics

Advertisement
UsernamePublicRestriction

Register

SC064814

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel